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Purpose: Epileptic seizures are frequent manifestations after hematopoietic stem cell transplantation
(HSCT). In this retrospective single-center study we evaluated electroclinical features and analyzed
etiologies and outcome of seizures after pediatric HSCT.
Methods: Of 261 children transplanted between 2000 and 2010, we identiﬁed and analyzed data of 28
patients with seizures within a year from HSCT.
Results: Most frequent etiologies were posterior reversible encephalopathy syndrome (PRES, 14
patients) and central nervous system (CNS) infections (4 patients). Seizures were the presentation of the
underlying complications in 22 patients. Sixteen episodes of status epilepticus were identiﬁed. Seizures
secondary to PRES were usually longer and associated with non-convulsive signs. Early neuroimaging
and EEG monitoring proved to be crucial to diagnose and treat seizures and their causes. No patients
developed epilepsy suggesting that chronic antiepileptic therapy is not necessary in these patients.
Overall survival was 32.3% over 5 years in patients with seizures and 45.8% in patients without seizures
(p < 0.05). Multivariate statistical analysis identiﬁed as independent risk factors for seizures a diagnosis
of non-oncological disease and cord blood stem cell transplantation.
Conclusions: Seizures in transplanted children are a severe event and are associated with high morbidity
and poor outcome. In particular, patients with non-oncological diseases and cord blood stem cell
transplantation have to be considered at high risk of seizures. Moreover, this study underlines the
importance of early recognition of non-convulsive clinical signs and of EEG monitoring for a prompt
diagnosis and an appropriate management of seizures and their causes.
 2013 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Pediatric hematopoietic stem cell transplantation (HSCT), in
particular allogeneic HSCT, is associated with a large spectrum of
neurologic complications that signiﬁcantly contribute to patients’
morbidity and mortality. The most frequent neurologic complica-
tions are CNS infections, cerebrovascular or metabolic events, and
neurotoxicity of immunosuppressive agents manifesting as
posterior reversible encephalopathy syndrome (PRES).1–4
Seizures are frequent clinical manifestations of neurological
complications after pediatric HSCT: seizures are reported in 6.9–
11.7% of transplanted patients and in 52.6–75.0% of patients with
neurological complications.1,4–8 Seizures can be the presenting and* Corresponding author at: Pediatric Neurology Unit, S. Orsola Malpighi Hospital,
University of Bologna, Via Massarenti 11, 40100 Bologna, Italy.
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http://dx.doi.org/10.1016/j.seizure.2013.11.003main manifestations of neurological complications after HSCT, and
especially in the case of status epilepticus (SE) appear to have a
high potential for morbidity.9 However, there are no studies in
literature that focus on seizures after pediatric HSCT and no
diagnostic and therapeutic approaches have been proposed in this
ﬁeld; furthermore, seizures in these patients have usually been
analyzed based on clinical records without a careful semeiological
and electroencephalography (EEG) evaluation.
The aim of the present study was to evaluate clinical and EEG
features and analyze the etiology and outcome of epileptic seizures
after pediatric HSCT in order to favor a prompt recognition and a
correct treatment of seizures and of their causes.
2. Patients and methods
Between January 2000 and December 2010, 345 consecutive
HSCT procedures were performed in 261 patients at the Pediatric
Hematopoietic Stem Cell Transplantation and Cell Therapy Unit of
the University of Bologna S. Orsola-Malpighi Hospital, Bologna.
175 underwent auto-HSCT and 170 allo-HSCT (16 haploidenticalvier Ltd. All rights reserved.
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HSCT, source of stem cells, donors, conditioning, anti-graft versus
host disease (anti-GvHD) prophylaxis, cytomegalovirus reactiva-
tion and neurological complications are detailed in Table 1.
We used computerized EEG and Cell Therapy Unit databases to
retrospectively identify patients aged 0–18 years with a deﬁnite
diagnosis of epileptic seizures within a year from HSCT. We
excluded patients with paroxysmal events of non-epileptic origin.
We collected information regarding patient’s age, sex, underlying
disease, transplant features (type of HSCT, source of stem cells,
donors, conditioning, anti-GvHD prophylaxis), characteristics of
seizures (etiology, time from HSCT procedure, semiology, duration,
ictal and post ictal EEGs, neuroimaging) and outcome.
An antiepileptic prophylaxis with valproic acid was given to all
patients treated with busulphan (BU) as conditioning regimen.Table 1
Clinical and transplant characteristics of the groups of children with and without
seizures.
Group without
seizures n = 317
Group with
seizures n = 28
Sex
M/F 187/130 17/11
Age at the transplant (years)
Mean  SD 8  5.4 8  5
Diagnosis
Oncological disease 298 21
ALL 67 5
AML 32 8
Lymphoma 22 2
Soft tissue sarcomas 76 2
Tumors of CNS 43 3
Neuroblastoma 42 –
Others 16 1
Non-oncological diseases 19 7
Type of HSCT
Autologous 170 5
Allogeneic 147 23
Related 60 7
Unrelated 64 16
Source of stem cells
BM 104 16
PBSC 180 7
CBSC 5 5
Conditioning regimen
Bu-based 133 15
TBI-based 30 –
Others 154 13
CMV positive/reactivation 94/33 10/7
aGVHD 43 6
GVHD prophilaxis
MTX-CSA 82 12
CSA-mPDN 9 5
CSA/FK 44 7
CNS complications
PRES 0 14
Symptomatic CNS
involvement of
underlying disorders
3 4
Infection 4 4
Drug toxicity 0 2
Metabolic disturbances 0 1
Other/unknown etiology 2 4
pts: patients, ALL: acute lymphoblastic leukemia, AML: acute myeloid leukemia,
PBSC: peripheral blood stem cells, BM: bone marrow, CBSC: cord blood stem cells,
BU: busulphan, TBI: total body irradiation, CMV: cytomegalovirus, CNS: central
nervous system, MTX: methotrexate, CSA: cyclosporine, FK: tacrolimus, mPDN:
methylprednisolone. PRES: posterior reversible encephalopathy syndrome.Etiology of seizures was classiﬁed as follows:
Transplant related etiologies
 PRES associated with calcineurin inhibitors neurotoxicity. PRES
was deﬁned as a clinical-radiological entity characterized by
encephalopathy, headache, seizures and visual disturbances
with a typical imaging pattern showing cortical and subcortical
potentially reversible vasogenic edema, most commonly affect-
ing the posterior regions of the brain.10
 Dimethylsulfoxide (DMSO) and/or BU neurotoxicity.
 Metabolic disturbances.
 CNS infections.
 Cerebrovascular disorders.
 Encephalopathy of unknown etiology.
Non-transplant related etiologies
 Symptomatic epilepsy secondary to CNS involvement of
underlying disorder. Seizures in patients with previously
diagnosed epilepsy were considered in the study and classiﬁed
as non-transplant related neurological complications of HSCT.
Semiology of seizures was classiﬁed in accordance with ILAE
classiﬁcation.11
Status epilepticus (SE) was deﬁned as 30 min of continuous
seizure activity or a series of seizures without return to full
consciousness between seizures.12 Non-convulsive SE (NCSE) was
deﬁned as impaired consciousness for more than 30 min, with
some epileptic electrographic seizure activity without overt
convulsions but with a plethora of different cognitive, behavioral,
and minor motor features.13 Seizure activity during NCSE was
deﬁned according to Kaplan EEG criteria.14
In the case of a seizure, the following investigations were
performed: whole blood count, glycemia, electrolytes, C-reactive
protein, blood gas analysis, transaminases, urea, creatinine. Blood
pressure was tested at least daily in all patients. Lumbar puncture
was performed in the case of suspected viral or bacterial CNS
infection.
Our EEG practice is to perform a bedside recording early on
after the occurrence of neurological signs or symptoms or at the
onset of consciousness alteration. Standard EEG tracings are
obtained for at least 30 min. If the ﬁrst EEG recording shows
abnormalities, serial EEGs are repeated on the following days. If
seizure activity or SE is detected, a prompt pharmacological
treatment is provided and EEG is continued to monitor the effects
of therapy. EEG studies were reviewed by a pediatric neurologist
experienced in pediatric EEG.
Neuroimaging was obtained in all children with suspected
neurological complications. Computerized tomography (CT) scans
of the brain were performed as soon as possible in the case of focal
neurological signs or prolonged consciousness alteration, to
exclude cerebrovascular disorders. Magnetic resonance imaging
(MRI) techniques included FSE and ﬂuid attenuated inversion
recovery (FLAIR), T2WI, diffusion weighted images (DWI), T1WI,
and MR angiography 3D TOF. Neuroimages were reviewed by a
pediatric neuroradiologist.
3. Statistical methods
Patients were divided into those with seizures and those
without seizures.
To determine the risk factors for seizures in HSCT children each
variable was initially analyzed with a univariate model using Cox
regression. Variables with p < 0.05, according to univariate
analyses, were entered in a Cox regression model for multivariate
analysis.
Survival rates were estimated using the Kaplan–Meier method
using the GraphPad Prism version 6.0 software.
Table 2
Clinical, EEG and MRI features of patients with seizures of known etiology.
Posterior reversible
encephalopathy
syndrome (PRES) N = 14
DMSO or BU
neurotoxicity N = 2
Metabolic
disturbances N = 1
CNS infections N = 4 Symptomatic epilepsy
– CNS involvement of
underlying disorder N = 4
Age; median (range) 8.5 (1–17) 12 11 9.5 (4–17) 8 (1–16)
Type of HSCT 14: allo-HSCT 1: auto-HSCT
1: allo-HSCT
1: allo-HSCT 4: allo-HSCT 2: auto-HSCT
2: allo-HSCT
Days after HSCT;
median (range)
65 (5–352) 1 (3–1) 122 90 (10–330) 102.5 (1–350)
First seizure onset 7: gaze deviation
3: gaze deviation
+ impairment of
consciousness
2: GTCS
1: oculoclonic movements
1: visual hallucination
1: gaze deviation
(DMSO)
1: GTCS (BU)
1: gaze deviation 2: GTCS (EBV-PTLD, S. Aureus)
1: impairment of consciousness +
automatisms (abscess)
1: emyclonic seizure (Aspergillus)
2: emyclonic seizure
1: impairment of
consciousness
1: gaze deviation +
altered consciousness
Evolution to a bilateral,
convulsive seizure
6 1 1 1 1
Status epilepticus
(CSE/NCSE)
12 (8/4) – – 1(1/0) 1(0/1)
Ictal EEG 6: rhythmic S and SW
involving P-O and/or
T-O regions
– – – 2: rhythmic S and
SW involving C regions
(emyclonic seizures)
Post-ictal EEG 14: Slowing prevalent in
posterior regions.
5: PLEDs
Focal (DMSO) or
diffuse (BU)
slowing
Diffuse slowing Focal (EBV-PTLD, abscess, Aspergillus)
or diffuse (S. Aureus) slowing
Focal slowing
Neuroimaging 14: Posterior
predominant pattern of
cortical-subcortical
involvement
(vasogenic edema)
Normal Normal 1: Focal (F) localization (EBV-PTLD)
1: abscess lesion
1: diffuse edema (S. Aureus)
1: mycetomas (Aspergillus)
3: CNS localization
of underlying disorder
1: not performed
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Thirty-eight neurological complications after HSCT were
observed in 37 of the 261 patients (14.2%) who underwent HSCT
in our Unit from January 2000 to December 2010.
A total of 61 seizures were observed in 28 patients; in 24, seizures
were a manifestation of transplant related neurological complica-
tions; the remaining four patients had a previous diagnosis of
epilepsy secondary to CNS disease before HSCT. Ten of the 28
patients with seizures have been described in a previous paper.9
Patient features, with clinical and transplant data are described
in Table 1.
4.1. Etiology of seizures
Seizure features are described in Table 2.
PRES was the etiology of seizures in 14 patients (associated with
CsA in 13 cases and with FK506 in 1 case); CNS infections in
4 patients (S. aureus meningoencephalitis, Aspergillus encephalitis,
brain abscess, Epstein Barr Virus-post-transplant lymphoproli-
ferative disorders [EBV-PTLD]); DMSO, BU and metabolic distur-
bance (hypomagnesaemia) in 1 patient; in 4 patients seizures
occurred during an encephalopathy of unknown origin. One
patient was considered twice because she presented with seizures
as a manifestation of PRES and three months later she relapsed
with seizures secondary to CNS infection. The remaining four
patients had a previous diagnosis of epilepsy secondary to CNS
disease before HSCT.
4.2. Timing of seizure presentation
Patients developed seizures following HSCT after a median
period of 78 days (range 3; +352), in case of PRES it was 65 days
(range 5–352). See Fig. 1 for details.
Seizures were the presentation of underlying neurological
complications in 22 patients. In particular 11 out of 14 patients
with PRES presented with seizures.4.3. Frequency and semiology of seizures
Sixteen patients had a single seizure. 12 patients had repeated
seizures (range: 2–8 seizures). In 10 out of these 12 patients,
seizures recurred within the ﬁrst week after onset. In the other 2
patients, both with PRES, an isolated and apparently unprovoked
seizure occurred 50 and 76 days respectively after the ﬁrst seizure.
In most patients the onset of the ﬁrst seizure was character-
ized by non-convulsive focal signs such as gaze deviation,
oculoclonic movements, visual hallucinations sometimes asso-
ciated with altered mental status. Non-convulsive clinical
features were observed at onset of seizure in 20 patients and
in particular in 12 cases of PRES. In detail, in 9/28 patients
seizures onset was characterized by gaze deviation, 7 of them
had PRES; in 5/28 patients, seizures developed with gaze
deviation associated with impairment of consciousness, 3 had
PRES. In 2 cases of PRES seizures started respectively with
oculoclonic movements and visual hallucinations; seizures
started with impairment of consciousness in 4/28 patients.
Evolution to a bilateral, convulsive seizure was signaled in
10 patients. The onset of seizures was characterized by motor
involvement in 8 patients: generalized tonic-clonic seizures in
5/28 patients and emiclonic seizures in 3/28.
4.4. Status epilepticus
16 episodes of SE in 14 patients were identiﬁed: 10 convulsive
SE and 6 NCSE. Median duration of SE was 175 min (range
40–1000 min). EEG monitoring was used in patients with NCSE
during the ictal and early post-ictal phases to assess the efﬁcacy of
therapeutic intervention. 12 patients with SE had a diagnosis
of PRES and 2 presented two SE.
4.5. Ictal and postictal EEG
Ictal EEGs were obtained in 9 patients; in 6 of them etiology was
PRES, in 2 symptomatic epilepsy secondary to CNS involvement of
Fig. 1. A suggested timetable for the etiology of seizures in pediatric patients who underwent HSCT. Legend: PRES: Posterior Reversible Encephalopathy Syndrome, FK 506:
Tacrolimus, CMV: Cytomegalovirus, HHV6: Herpes Human Virus 6, Herpes Human virus 8, VZV: Varicella Zoster Virus, EBV: Epstein Barr Virus, CNS: Central Nervous System.
^: Patients with seizures in our cohort.
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all cases of PRES ictal EEG showed rhythmic spikes involving
unilateral or bilateral parieto-occipital or temporal-occipital
regions. All patients were closely followed-up by repeated EEG
in the early post-ictal period. At least one EEG was obtained for all
patients in the ﬁrst 48 h after ﬁrst seizure: in all cases it was
characterized by focal or generalized slow electrical activity; in
patients with PRES slowing was more evident on posterior regions
of the brain. PLEDs associated with slow activity were recorded in 5
patients, all with PRES.
4.6. Treatment
Longer or repeated seizures were stopped in all but one patient
with the use of antiepileptic drugs (AEDs); in all patients we used
as ﬁrst line treatment benzodiazepines (diazepam and/or mid-
azolam): 16 patients required repeated administrations of
benzodiazepines and/or administration of phenytoin i.v. Only
one patient with refractory SE needed the use of an anesthetic
agent (propofol). 12/28 patients needed intensive care unit (ICU)
admission to support vital functions; 10 of them had PRES.
The causes of the seizures were treated: electrolytic imbalance
was corrected, in patients with PRES the ongoing calcineurin
inhibitor treatment was stopped and subsequently replaced by a
different immunosuppressant agent and in patients with CNS
infection speciﬁc treatment with antibiotic or anti-fungal or
antiviral drugs was administered based on the underlying disease.
All patients were treated with AEDs during the acute phase
and in 11 cases a prophylaxis with AEDs was continued after
the resolution of the neurological complication for a median time
of 2 months (range 2 weeks–18 months).
4.7. Neuroimaging
Neuroimaging studies were performed in 26 patients. Early CT
scans were performed in 12 patients with focal neurological signs
or prolonged consciousness alteration. MRI was performed in the
ﬁrst 72 h after seizure in 21 patients. In 2 patients brain imagingwas not obtained: in one patient because of the critical clinical
conditions; the other had previously diagnosed epilepsy. In the
cases of PRES brain imaging was characterized by a posterior-
predominant pattern of cortical-subcortical involvement: focal
lesions conﬁned to parietal and/or occipital lobes and more
extensive multifocal or diffuse lesions which involved frontal and
temporal lobes, cerebellum and basal ganglia were observed. In
one patient we observed an acute PRES-related intraparenchymal
hemorrhage in the left temporal lobe. No correlation was observed
between the duration of seizures and the extension of brain
involvement.
In patients with CNS infections MRI imaging showed: a focal
lesion with perilesional edema in the case of EBV-PTLD; an abscess
lesion; diffuse edema in a patient with S. Aureus encephalitis;
mycetomas in the case of Aspergillus infection. Cerebral imaging
was negative in patients with a diagnosis of electrolyte distur-
bance, DMSO and BU toxicity, in 2 patients with encephalopathy of
unknown etiology and in one patient with seizures due to
underlying disease (meningeal leukemia). In the cases of CNS
malignancies MRI showed the tumor lesion or the surgical lesion if
the tumor was removed.
4.8. Risk factors
Univariate analysis in the whole population recognized the
following possible risk factors for seizures: a diagnosis of non-
oncological disease, allogeneic HSCT, cord blood stem cell (CBSC)
transplantation and BU-based conditioning regimen. Multivariate
analysis identiﬁed as independent risk factors for seizures (in the
whole population and in allo-HSCT population) a diagnosis of non-
oncological disease and CBSC transplantation. See details in
Table 3.
4.9. Outcome
By December 2010 17/28 patients had died. They died after a
mean period of 9 months from HSCT due to complications linked to
the underlying disease or to other HSCT complications. Two
Table 3
Risk factors for seizures in transplanted children by univariate and multivariate analysis.
Allogeneic/autologous HSCT (N = 345)
Univariate Multivariate
Odds ratio 95% CI P value Hazard 95% CI P value
Diagnosis
Non-oncological 5.76 2.15–15.44 0.000 4.59 1.53–13.79 0.007
Type of HSCT
Allogeneic 5.69 2.10–15.35 0.001 2.83 .90–8.90 0.075
SSC
CBSC 6.54 2.06–20.75 0.001 4.80 1.38–16.69 0.013
Conditioning regimen
BU-based 2.55 1.05–6.18 0.038 1.56 .58–4.22 0.378
Allogeneic HSCT (N = 170)
Univariate Multivariate
Odds ratio 95% CI P value Hazard 95% CI P value
Diagnosis
Non-oncological 3.13 1.12–8.73 0.028 4.19 1.42–12.29 0.009
SSC
CBSC 3.58 1.09–11.67 0.034 5.09 1.47–17.58 0.010
BU: busulphan, CBSC: cord blood stem cells, HSCT: hematopoietic stem cell transplantation, SSC: source of stem cells, TBI: total body irradiation.
Fig. 2. Kaplan–Meyer overall survival (OS) curve in patients with and without
seizures.
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fungal infection, the other due to EBV-PTLD with cerebral
localization. Overall survival for patients with seizures was
32.3% over 5 years compared to 45.8% in patients without seizures
(p < 0.05) (see Fig. 2). Patients with SE had a poorer prognosis:
11/14 died against 6/14 patients without SE. No patients developed
epilepsy during the follow-up period.
5. Discussion
Our data show that seizures are a frequent manifestation of
neurological complications after pediatric HSCT. In most cases
seizures were the ﬁrst manifestation of underlying neurological
complications; moreover, they were often repeated and/or long
lasting requiring intensive treatment. These data emphasize the
importance of timely diagnosis and treatment of seizures and their
causes. This study is the ﬁrst attempt to investigate clinical and
EEG features and analyze etiologies of epileptic seizures after
pediatric HSCT.
In the present study seizures occurred in 10.7% of all patients
and in 73.6% of patients with neurological complications after
HSCT; in the literature seizures are reported in 6.9–11.7% of
transplanted patients and in about 52.6–75.0% of patients with
neurological complications.1,4–8 The high incidence of seizures in
our population may be partially explained by the different
populations and deﬁnitions of neurological complications used
in the studies. However, we suggest that our practice of the routine
use of EEG monitoring may have improved the detection ofnon-convulsive seizures and NCSE in our population. In fact, we
observed at onset of seizures non-convulsive clinical features in
20/28 patients. In our experience the use of EEG monitoring at the
occurrence of neurological signs or symptoms is a useful and
practical approach to diagnose promptly and treat mildly
symptomatic seizures or NCSE in children after HSCT.
Moreover the data of the present study conﬁrm that long lasting
non-convulsive seizures beginning with subtle and stereotyped
clinical signs such as gaze deviation, oculoclonic movements and
mental status changes associated with a particular localization of
EEG ictal and/or postictal abnormalities (rhythmic epileptiform
activity, PLEDs and/or slowing) in the posterior regions of the brain
are particularly suggestive of PRES, as we have already described in
a recent paper.9 The recognition of this pattern will enable clinicians
to suspect PRES also before neuroradiological conﬁrmation.
PRES occurred exclusively in allo-HSCT patients and was the
main etiology of seizures in our population. PRES related to
cyclosporine or FK506 has been recognized as a major cause of
seizures after HSCT.2,4,15 PRES was a cause of early seizures,
occurring in the ﬁrst 100 days after HSCT in all patients but one.
Interestingly, in our study all 14 patients with PRES had seizures,
and in 11 of them seizures were the ﬁrst manifestation, under-
lining the particular epileptogenicity of this encephalopathy.16,17
Seizures due to DMSO and or BU neurotoxicity, metabolic
disturbances and CNS infections showed in our patients less
distinctive electroclinical features than PRES. However, other
characteristics such as timing, clinical features, laboratory or
neuroradiological examinations were useful in our experience to
suggest and conﬁrm etiological diagnosis. Very early seizures
occurring suddenly during conditioning in a previously neurologi-
cally intact patient were usually secondary to DMSO or BU
neurotoxicity3,18,19; in the case of metabolic disturbance diagnosis
was easily obtained by laboratory examinations. Seizures in the
setting of CNS infections were associated with other suggestive
laboratory data and/or clinical signs such as fever and were rarely
the ﬁrst manifestation of the neurological complication.
Neuroimaging, and in particular MRI, was conﬁrmed as a
fundamental tool to obtain a correct diagnosis in neurological
complications after HSCT. According to literature data, MRI was
normal in cases of DMSO and BU toxicity and in metabolic
disturbances and showed very typical and speciﬁc ﬁndings in PRES
and in CNS bacterial and mycotic infections.20 Although in our
experience we observed only one patient with PRES-related
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neuroimaging (CT and/or MRI) in patients with focal neurological
signs to exclude cerebral bleeding. A rapid clinical evaluation at the
occurrence of neurological signs and symptoms, including early
neuroimaging, EEG monitoring and laboratory tests are mandatory
for a correct etiological diagnosis of seizures in HSCT setting.
SE, often but not always secondary to PRES, was observed in half
of our patients. SE was recently described as the main manifesta-
tion of PRES after pediatric HSCT.9 SE is a potential life-threatening
event and can lead to neurologic sequelae such as secondary
epilepsy, cognitive deterioration, behavioral problems and focal
neurologic deﬁcits.21 Our data show that SE occurring after HSCT is
usually not easy to treat and may require intensive care
management to support vital functions.
The risk factors for seizures after pediatric HSCT identiﬁed by
multivariate statistical analysis in our population (diagnosis of
non-oncological disease and CBSC transplantation) differ from
those recently described by other authors in adult patients.8 This
fact may be explained by the diversity of transplant procedures
and population characteristics between pediatric and adult HSCT
patients. Other factors that were suspected to increase the risk of
seizures in transplanted children, such as BU-based conditioning
regimen and allogeneic transplantation, were associated with
seizures in univariate analysis but were not statistically signiﬁcant
in multivariated analysis.
In our experience a very high mortality rate was observed in
children presenting seizures after HSCT. A similar mortality rate
has been described in adult patients with seizures after allo-HSCT.8
In interpreting these data we have to take into account that severe
neurological complications have been described as a possible cause
of increased morbidity and mortality after pediatric allo-HSCT.1,2
Moreover, long lasting seizures are known to be related to a poor
outcome in critically ill patients22 and our results conﬁrm that SE is
associated with a poor prognosis in transplanted children. On this
basis, we strongly suggest that a prompt and aggressive acute
antiepileptic treatment should be ensured in patients with
seizures after HSCT.
Data are lacking in the literature about how long to continue
AEDs therapy after occasional seizures associated with neurologi-
cal complications. Some authors suggested continuing the
antiepileptic therapy on a long term basis in pediatric patients
with PRES.23 However, considering the occasional/provoked
nature of the seizures, in most of our patients prophylactic
treatment with AEDs (benzodiazepines and/or phenytoin) was
usually used only during the acute phase of the neurological
complication. Moreover, no patients with seizures secondary to
neurological complications of HSCT developed epilepsy during the
follow-up. We suggest that prolonged prophylactic treatment with
AEDs is not needed in patients with occasional/provoked seizures
after HSCT and it should be considered in the event of a later
development of secondary epilepsy.
6. Conclusions
This study shows that seizures are a frequent and severe event
after pediatric HSCT. PRES was the main etiology of seizures in our
population. Seizures secondary to PRES showed a particular and
recognizable electroclinical pattern, recognition of which may
make clinicians suspect PRES also before neuroradiological
conﬁrmation. In our experience the early use of EEG monitoring
in addition to careful clinical, laboratory tests and neuroimaging
work-up is required in patients with seizures after HSCT to
diagnose and treat correctly seizures and their causes. Finally, we
suggest that, although a prompt and aggressive acute antiepileptictreatment has to be ensured, a long lasting prophylactic therapy
with AEDs is not usually necessary in these patients.
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